FAQ: Teplizumab and Its Expanded FDA Indication

FDA expands teplizumab to age 1 year for stage 2 type 1 diabetes—pharmacists must learn dosing, infusion logistics, and safety monitoring.

This FAQ was fact-checked by Jennifer Goldman, PharmD, CDCES, BC‑ADM, FCCP.